Fibrinogen degradation product 16.98mg/L indicates that there is hyperfibrinolysis in the body, which may have occurred in pulmonary embolism, intravascular thrombosis and other thrombotic diseases, or the body may be in the dispersive intravascular coagulation hypercoagulable period.
Fibrinogen degradation product is the product of large amount of fibrinogen degradation caused by hyperfibrinolysis, normal human fibrinogen degradation product is often less than 5mg/L, and 16.98mg/L is significantly more than 5mg/L, suggesting that hyperfibrinolysis, including primary hyperfibrinolysis and secondary hyperfibrinolysis, of which secondary hyperfibrinolysis is more common.
When intravascular thrombosis, pulmonary embolism or disseminated intravascular coagulation (hypercoagulable phase) occurs, the body will have hyperfibrinolysis, which will be manifested as a significant increase in fibrinogen degradation products. Diseases such as intravascular thrombosis and pulmonary embolism can be clarified by vascular ultrasound and pulmonary artery CTA.
The diagnosis of disseminated intravascular coagulation (hypercoagulable phase) needs to be analyzed comprehensively with the patient’s condition and coagulation routine and other tests. It can occur in patients with acute promyelocytic leukemia, severe infections, and major surgical operations, and requires immediate treatment for the specific cause of the disease.
It is recommended that the patient should go to the hematology department in time to improve the relevant examination to clarify the specific cause of the disease, and the specialist should analyze the condition and treat the cause of the disease as soon as possible.